Can AI Review eTMF Documents Before a Regulatory Inspection?

A Trial Master File is the complete documentary record of a clinical trial. It must demonstrate that the trial was conducted in compliance with GCP guidelines and applicable regulations. When an FDA, EMA, or MHRA inspector reviews a trial, the eTMF is the primary evidence base. Gaps, inconsistencies, missing documents, or metadata errors in the TMF are among the most common sources of inspection observations.

The challenge for clinical operations teams is that inspection readiness review is expensive to perform well. A comprehensive QC review of a large eTMF, covering document completeness, metadata accuracy, version control, and cross-referencing against the trial protocol, can absorb a QC team for several days or weeks. For organisations running multiple trials simultaneously, this creates a genuine capacity problem. AI agents address this directly.

What Inspectors Look for in an eTMF

Understanding what AI agents are reviewing requires understanding what inspectors examine. The core areas are:

• Document completeness: Is every required document present, for every trial site, for the entire duration of the trial? Missing informed consent forms, investigator CVs, protocol amendments, or safety reports are common findings.
• Metadata accuracy: Are documents filed in the correct TMF reference model location? Are dates, version numbers, and document types correctly recorded?
• Version control: When a protocol was amended, are all superseded versions clearly identified and the current version correctly marked?
• Audit trail integrity: Does the system record who accessed or modified documents, and when? Are any modifications after the trial closure date adequately explained?
• Cross-document consistency: Do dates and details in one document (for example, the protocol) align with corresponding entries in other documents (site activation logs, monitoring visit reports)?

The Manual Review Problem

Manual eTMF review is not just slow. It is also inconsistent. Different reviewers apply different standards. Under time pressure, reviewers may miss low-salience gaps that inspectors specifically look for. And manual review of a large eTMF does not scale. A trial with 50 sites and three years of documentation may contain tens of thousands of documents. Reviewing each one systematically is not realistic without automation.

The consequence is that many organisations approach inspections with eTMFs they know are imperfect but have not had time to fully remediate. Inspectors find what QC teams did not have capacity to fix.

How AI Agents Approach eTMF Review

AI agents deployed across an eTMF work differently from human reviewers. They can process the full document set in hours rather than days, applying consistent logic to every document without fatigue or inconsistency. The approach has several components:

Completeness checks: The agent maps the eTMF against the expected document set for the trial type, phase, and number of sites. Every expected document is checked for presence. Missing documents are flagged with their TMF reference model location and the site or time period to which they relate.

Metadata validation: Document metadata is validated against filing rules. Misfiled documents, incorrect version numbering, and date discrepancies are identified and reported by location.

Cross-document consistency: The agent extracts key data points from multiple document types and cross-references them. Protocol amendment dates are checked against site notification logs. Investigator qualification dates are checked against delegation of authority logs.

Risk prioritisation: Findings are not just enumerated. They are organised by document type, site, and risk level, so the QC team can focus remediation effort on the highest-risk gaps first.

What the Output Looks Like

The output of an AI eTMF review is a structured findings report: a prioritised list of gaps and inconsistencies, each linked to the specific document or document location where the issue was identified. The QC team reviews the findings, verifies the ones requiring human judgement, and proceeds directly to remediation. The full audit trail of the AI review is retained, documenting what was checked, when, and what was found.

Timelines and Practical Considerations

For most clinical eTMFs, an AI review can be completed in hours to a day, depending on document volume and the complexity of cross-referencing required. This compresses the inspection readiness window significantly. Instead of beginning eTMF QC review six weeks before an inspection, teams can run AI review on a rolling basis, or initiate a comprehensive review immediately upon receiving inspection notification.

One important consideration: AI eTMF review is not a substitute for ongoing TMF oversight. The FDA and EMA expect TMFs to be inspection-ready throughout the trial, not just in the weeks before an announced inspection. Teams that run AI review periodically during the trial catch and remediate issues earlier, reducing the remediation burden at trial closure.